Taking into account that the tumor-specific receptor subtype highly determines the APN/CD13 binding potential of NGR–drug complexes [49], the assessment of the tumor receptor profile prior to the development of NGR-based diagnostic or therapeutic compounds is required. This evidence concerns the gene RTN4R and neoplasm.